COSCIENS Biopharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSCI research report →
Companywww.cosciensbio.com
COSCIENS Biopharma Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
- CEO
- Anna Elizabeth Biehn
- IPO
- 1996
- Employees
- 40
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $8.57M
- P/E
- -2.47
- P/S
- 1.28
- P/B
- 0.48
- EV/EBITDA
- 1.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 95.06%
- Op Margin
- -400.36%
- Net Margin
- -78.93%
- ROE
- -13.16%
- ROIC
- -49.62%
Growth & Income
- Revenue
- $13.78M · 92.96%
- Net Income
- $-15,309,000 · -339.28%
- EPS
- $-5.93 · -213.76%
- Op Income
- $-26,280,973
- FCF YoY
- -376.06%
Performance & Tape
- 52W High
- $4.61
- 52W Low
- $1.75
- 50D MA
- $3.46
- 200D MA
- $3.18
- Beta
- 1.85
- Avg Volume
- 9.72K
Get TickerSpark's AI analysis on CSCI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CSCI Coverage
We haven't published any research on CSCI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CSCI Report →